相关实验视频

Updated: Sep 16, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

疫苗诱导对R21/Matrix-M的反应 - - 一个1b期年龄降级,剂量升级试验的样本分析

Caroline Bundi^1,2, Duncan Bellamy³, Elizabeth Kibwana¹

¹Centre for Geographic Medicine Research, Coast, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.

Frontiers in immunology

|July 11, 2025

概括

疟疾疫苗R21在儿童中有效,但抗体反应因年龄和辅助剂量而异. 需要进一步的研究来优化下一代疟疾疫苗.

科学领域:

免疫学免疫学免疫学
疫苗学疫苗学疫苗学
传染性疾病传染性疾病

背景情况:

与Matrix-M辅助的R21疟疾疫苗在第三阶段试验中显示出75%的有效性,并且是世卫组织对幼儿的建议.
针对NANP的抗体与保护有关,但年龄和先前免疫力等因素会影响疫苗反应.

研究的目的:

评估不同年龄组 (成年人,儿童,婴儿) 的R21/Matrix-M疫苗诱导的抗体数量和功能.
研究年龄,疫苗剂量和先前存在的免疫力对R21疫苗免疫性的影响.

主要方法:

抗体水平和功能 (补充固定,杂虫虫入侵抑制,贪) 在1期R21/Matrix-M试验的参与者中被测量.
使用ELISA评估了先前存在的疟疾暴露,并监测了抗HBsAgIgG水平.

主要成果:

R21/Matrix-M诱导的功能抗体 (CSP抗体) 在成年人中低于儿童和婴儿.
在婴儿中,较高的辅助剂量与增加的补体固定和体虫入侵抑制相关.
年龄和疫苗剂量显著影响了抗体的大小和功能,而狂热性并不总是与保护有关.

结论:

R21/Matrix-M在不同年龄组中具有免疫性,年龄和辅助剂量是影响抗体反应的关键因素.
优化辅助剂和疫苗剂量对于推动疟疾疫苗开发至关重要.
需要进一步的研究,以充分了解影响R21疫苗疗效的因素,并为下一代疟疾疫苗提供信息.

关键词:

R21 一个人的生活抗体是一种抗体.免疫性免疫性免疫性疟疾疟疾是一种疾病.过去的暴露过去的曝光.疫苗,疫苗的使用情况.

更多相关视频

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

相关概念视频

Vaccinations

Vaccinations

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...

Dose-Response Relationship: Overview

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...